Reid Merryman, MD, Discusses Autologous Stem Cell Transplantation for Patients with DLBCL


Merryman provided background for the study design investigating patients with relapsed or refractory diffuse large B-cell lymphoma.

Reid Merryman, MD, of the Dana-Farber Cancer Institute, spoke with CancerNetwork® to detail the study design for investigating the prognostic value of circulating tumor DNA among patients with diffuse large B-cell lymphoma (DLBCL) presented at the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition.


Currently, the standard of care for patients with relapsed or refractory DLBCL is salvage chemotherapy and autologous stem cell transplantation for patients who are fit and chemo[therapy] sensitive. But unfortunately, a lot of patients will relapse following autologous stem cell transplant, even patients who have a good response on their pre-transplant PET scan. The goal of this study was to use circulating tumor DNA to identify patients who may be at higher risk of relapse from autologous stem cell transplantation and we were able to look at samples collected at a few different time points. About 100 patients had samples collected, [and] we had bank samples from their apheresis stem cell sample . And then about 55 patients had serially collected samples after transplant, these were peripheral blood samples. We were able to analyze both to look for the presence of circulating tumor DNA using immunoglobulin-based next-generation sequencing in collaboration with adaptive bio technologies.

Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content